Maternal Streptococcus agalactiae colonization in Europe: data from the multi-center DEVANI study

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F75010330%3A_____%2F25%3A00014967" target="_blank" >RIV/75010330:_____/25:00014967 - isvavai.cz</a>

Result on the web

<a href="https://link.springer.com/article/10.1007/s15010-024-02380-0" target="_blank" >https://link.springer.com/article/10.1007/s15010-024-02380-0</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s15010-024-02380-0" target="_blank" >10.1007/s15010-024-02380-0</a>

Result language

angličtina

Original language name

Maternal Streptococcus agalactiae colonization in Europe: data from the multi-center DEVANI study

Original language description

Introduction Despite national guidelines and use of intrapartum antibiotic prophylaxis (IAP), Streptococcus agalactiae (group B streptococci (GBS)) is still a leading cause of morbidity and mortality in newborns in Europe and the United States. The European DEVANI (Design of a Vaccine Against Neonatal Infections) program assessed the neonatal GBS infection burden in Europe, the clinical characteristics of colonized women and microbiological data of GBS strains in colonized women and their infants with early-onset disease (EOD). Methods Overall, 1083 pregnant women with a GBS-positive culture result from eight European countries were included in the study. Clinical obstetrical information was collected by a standardized questionnaire. GBS strains were characterized by serological and molecular methods. Results Among GBS carriers included in this study after testing positive for GBS by vaginal or recto-vaginal sampling, 13.4% had at least one additional obstetrical risk factor for EOD. The five most common capsular types (i.e., Ia, Ib, II, III and V) comprised similar to 93% of GBS carried. Of the colonized women, 77.8% received any IAP, and in 49.5% the IAP was considered appropriate. In our cohort, nine neonates presented with GBS early-onset disease (EOD) with significant regional heterogeneity. Conclusions Screening methods and IAP rates need to be harmonized across Europe in order to reduce the rates of EOD. The epidemiological data from eight different European countries provides important information for the development of a successful GBS vaccine.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30303 - Infectious Diseases

Project

—

Continuities

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Publication year

2025

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Infection

ISSN

0300-8126

e-ISSN

1439-0973

Volume of the periodical

53

Issue of the periodical within the volume

1

Country of publishing house

DE - GERMANY

Number of pages

9

Pages from-to

373-381

UT code for WoS article

001326892200001

EID of the result in the Scopus database

2-s2.0-85203329114